A healthy volunteer receives an intravenous infusion of mAb114 (Source: NIAID)
A Phase 1 clinical trial to test the safety of an antibody to use against Ebola outbreak has been successfully concluded by the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland (U.S.A. The treatment is based on the monoclonal antibody mAb114, which was isolated and characterized in Switzerland at the Institute for Research in Biomedicine (IRB Bellinzona, affiliated to USI Universitą della Svizzera italiana) in collaboration with Humabs BioMed SA, a subsidiary of Vir Biotechnology Inc. San Francisco, and with scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC); National Institute of Biomedical Research (INRB) in the DRC; and the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick, Maryland. The results published in The Lancet reveal that mAb114 appears to be safe, well tolerated, and easy to administer . Clinical Phase 1 design In the Phase 1 study, that began in May 2018, aimed at testing whether mAb114 is safe and how a person's body responds to it. Participants received a single intravenous infusion of mAb114, administered over approximately 30 minutes. Participants were divided into three groups that received different dosages.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
